- Diagnosis and treatment of chronic myelomonocytic leukemia - a view from clinical practice2016 | Publication without faculty affiliation
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | First Faculty of Medicine
- Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome2009 | Publication without faculty affiliation
- Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports2012 | First Faculty of Medicine
- Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax2022 | First Faculty of Medicine
- Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy2022 | Central Library of Charles University
- Sarcosine Degradation Pathway is Involved in the Epigenetics of Prostate Cells2017 | Faculty of Science, Second Faculty of Medicine
- Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways2022 | First Faculty of Medicine
- Immune deregulation in myelodysplastic syndromes - the role of cytokines and soluble adhesion molecules. A pilot study2023 | Faculty of Medicine in Hradec Králové
- Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis2019 | Faculty of Science, Second Faculty of Medicine
- Long-term treatment results of chronic myelomonocytic leukaemia in selected haematological centres2017 | Faculty of Medicine in Hradec Králové
- Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial2020 | Third Faculty of Medicine